Prenetics and Globally Renowned Scientist Prof. Dennis Lo Establish US$200m Joint Venture “Insighta” for Breakthrough Multi-Cancer Early Detection Screening
June 25, 2023 20:45 ET
|
Prenetics Limited
(Prof. Dennis Lo and Danny Yeung at Signing Ceremony) - Insighta is a 50/50 Joint Venture by Prenetics and Professor Dennis Lo. - Insighta is powered by technology developed by the Centre for...
Prenetics Announces First Quarter 2023 Financial Results
June 05, 2023 07:00 ET
|
Prenetics Limited
HONG KONG, June 05, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced financial...
Prenetics Announces Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023 08:49 ET
|
Prenetics Limited
LONDON and HONG KONG, March 14, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics and precision oncology company, today announced...
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
March 02, 2023 07:00 ET
|
Prenetics Limited
LONDON and HONG KONG, March 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics...
Prenetics to Participate Virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02, 2023 16:01 ET
|
Prenetics Limited
LONDON and HONG KONG, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, today announced that its management team will participate...
Prenetics Announces Dr. Bayju Thakar as Chief Executive Officer of Prenetics EMEA
January 19, 2023 05:00 ET
|
Prenetics Limited
LONDON and HONG KONG, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced an executive leadership change to ensure...
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
January 10, 2023 06:00 ET
|
Prenetics Limited
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global precision oncology marketFDA market authorization advances personalized...
Prenetics Acquires ACT Genomics, Creating a Leader in Comprehensive Cancer Genetics and Precision Oncology
December 16, 2022 06:27 ET
|
Prenetics Limited
Acquisition to bring germline and somatic testing, cell-free DNA-based (liquid biopsy), and tissue-genomic profiling onto a single platformCancer genomics testing is now standard practice for cancer...
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
November 30, 2022 09:15 ET
|
Prenetics Limited
LONDON and HONG KONG, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced that...
Prenetics Announces Record Third Quarter 2022 Financial Results and Raises Full Year 2022 Revenue and EBITDA Guidance
November 10, 2022 08:00 ET
|
Prenetics Limited
LONDON and HONG KONG, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a global leader in genomic and diagnostic testing, today announced its...